News

AmVac bags €11m funding
Enlarge image

FundingEUSwitzerland

AmVac bags €11m funding

21.06.2013 - Swiss vaccine developer AmVac AG has bagged EU funding in two FP7 projects worth €5.5m and €6m.

The projects aims to develop innovative vaccines against flu and leishmaniasis including Phase I safety testing. The first one of the 5-year projects is aimed at developing a universal flu vaccine that can be used over several years. While traditional flu vaccines target highly variable antigens on the virus' surface and must be adapted and newly produced each year, the new vaccine will be based on antigens that are well conserved across the strains and largely stable over time. AmVac will be involved in vaccine design and contributes its MALP adjuvant to optimize efficacy. Moreover, AmVac will support the establishment of GMP (Good Manufacturing Practice) vaccine manufacturing.

The second project targets leishmaniasis, an infectious disease transmitted by certain species of sand fly. It is found in parts of the tropics, subtropics and southern Europe. Currently, there is no vaccine available. A first-in-class vaccine could not only protect the local population but also tourists travelling to endemic regions. AmVac will support pre-clinical testing and manufacturing according to GMP standards.

Funds provided under the FP7 programme only require a 25% contribution in kind by small and medium-size companies such as AmVac. 'It is an excellent opportunity to leverage our investments and create significant potential for patients and investors - even more so, as both projects are expected to complete first clinical trials within the funding periods,' Melinda Karpati, CEO of AmVac comments.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/amvac-bags-eur11m-funding.html

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

BusinessEUGermanyUK

15.08.2014 Some of Europe’s biggest pharma companies are competing in a bidding war for US biotech Intermune Inc., Bloomberg reports, citing insider reports as the source.

ResearchEUGermanyUK

13.08.2014 The Ebola epidemic is still raging on in West Africa and thus far there is

neither vaccine nor cure for the viral disease. The only flickers of hope:

an experimental antibody serum and an early-stage vaccine.

BusinessFrance

11.08.2014 Will Sanofi succeed where Pfizer failed? The French pharmaceutical company has taken on the commercialisation of Mannkind Corporation’s inhaled insulin product Afrezza.

ResearchSwedenGermany

08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.

ResearchSwitzerlandDenmark

06.08.2014 Roche is re-expanding its involvement in RNAi technologies. The Swiss pharmaceutical company will pay up to €335m for the acquisition of the Danish company Santaris Pharma A/S.

ResearchUKSwitzerland

03.08.2014 In its efforts to become the leading country in genetic research, the UK has attracted investments worth more than £300m (€376m) to map 100,000 human genomes by 2017.

BusinessSpainUKSweden

31.07.2014 Astrazeneca is buying the rights to Almirall’s respiratory drugs in a deal worth up to €1.56bn.

BusinessFranceGermanySwitzerlandUK

30.07.2014 Rumours have it that French Danone wants to sell its medical nutrition business to US drugmaker Hospira for US$5bn in yet another tax inversion deal.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • SANTHERA80.00 CHF6.74%
  • WILEX2.26 EUR1.80%
  • ADDEX4.07 CHF1.75%

FLOP

  • MOLOGEN7.30 EUR-6.41%
  • 4SC1.16 EUR-3.33%
  • EVOLVA1.27 CHF-2.31%

TOP

  • MAGFORCE6.47 EUR19.8%
  • SANTHERA80.00 CHF15.1%
  • LONZA101.50 CHF9.7%

FLOP

  • WILEX2.26 EUR-31.1%
  • MOLOGEN7.30 EUR-22.8%
  • VITA 343.79 EUR-19.9%

TOP

  • SANTHERA80.00 CHF3802.4%
  • CO.DON2.50 EUR228.9%
  • PAION2.41 EUR186.9%

FLOP

  • CYTOS0.27 CHF-93.3%
  • MEDIGENE4.60 EUR-66.4%
  • THERAMETRICS0.08 CHF-46.7%

No liability assumed, Date: 20.08.2014